Bülent Aydemir

Bülent Aydemir

Auto-generated profile, based on publicly available information

Bülent Aydemir

Heart and Vascular Surgery Education and Research Hospital, Clinic of Chest Surgery Saglik Bilimleri (Health Sciences) University, Dr Siyami Ersek Chest Istanbul Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
ZSZuhal Kus Silav
Zuhal Kus Silav
MÇMakbule Çıkrıkçıoğlu
Makbule Çıkrıkçıoğlu
BABülent Aydemir
Bülent Aydemir
MYMehmet Yıldırım
Mehmet Yıldırım

19 December 2023 in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
Verified
Journal Article
Open access
PDF file
BOBurak Odabaşi
Burak Odabaşi
MYMehmet Yildirim
Mehmet Yildirim
İDİsmail Gülce DAL
İsmail Gülce DAL
MAM. Didem Aydemi̇r
M. Didem Aydemi̇r
KDKemal Demi̇rCan
Kemal Demi̇rCan
TOTamer Okay
Tamer Okay
Primary tumors of the chest wall are rare tumors comprising 5% of thoracic neoplasms. The current study was designed to evaluate the effect of histopathological subtype on the 5-year and 10-year overall survival and regional recurrence in primary malignant tumors of the chest wall. From December 2007 to December 2019, the data of 20 patients were analyzed. Overall survival rates, median overall survival, regional tumor recurrence and median disease-free survival rates were compared retrospectively between histopathological subtypes. Chondrosarcoma (n=7), desmoid tumor (n=6), undifferentiated pleomorphic sarcoma [(UPS), (n=4)], Ewing's sarcoma (n=1), malignant peripheral nerve sheath tumor (n=1), and liposarcoma (n=1) were the subtypes identified. A lower median overall survival was detected in the UPS histopathological subtype (p = 0.004). The 5 and 10-year overall survival rates in the chondrosarcoma group were 71% and 37%, respectively; desmoid tumors were found in 83% and 42%, respectively. There was no patient with 5-year survival in UPS. A shorter median overall survival was found in lateral wall masses compared to anterior and posterior wall masses (p = 0.001). During the follow-up, 10 patients (50%) died. It was observed that the median disease-free survival in the UPS subtype was shorter compared to the other subtypes (p = 0.002). The regional recurrence rate was 57%, 17% and 75% in chondrosarcoma, desmoid tumor and UPS, respectively. In UPS, a primary malignant tumor of the chest wall, 5-year and 10-year overall survival rates and median overall survival; it was found to be significantly shorter than the chondrosarcoma and desmoid tumor groups.

1 April 2024 in Demiroglu Science University Florence Nightingale Journal of Medicine
Verified
Journal Article
Open access
HYHalit Yardımcı
Halit Yardımcı
RURecep Ustaalioğlu
Recep Ustaalioğlu
BABülent Aydemir
Bülent Aydemir
MYMehmet YILDIRIM
Mehmet YILDIRIM
TOTamer Okay
Tamer Okay
Objectives: This study aims to clinically validate 8 th tumor, node, metastasis (TNM) staging for lung cancer on previously operated cases to evaluate its potential to achieve homogeneous patient groups and predict survival. Patients and methods: Between January 2009 and December 2016, 425 patients (356 males, 69 females; mean age: 61.5±9.4 years; range, 14 to 83 years) with non-small cell lung cancer were included in the study. Statistical evaluation was made by staging the postoperative pathological TNM according to the 7 th and 8 th TNM staging and comparing these two groups. All cases were evaluated according to the pathological TNM data obtained after the operation. The cases were staged twice according to the pathology results reports, by the 7 th and 8 th TNM. The distribution of patients in these two groups according to T parameter, N parameter, and stage is given. When staging changed, distribution changes between patient groups were evaluated. The survival distribution between the 7 th and 8 th stage groups was evaluated with the 5-year survival data obtained during follow-up. Results: No change was observed in any parameters or stages of 148 of 425 cases (34.8%) with the 8 th staging classification. When classifying according to the 8 th TNM in the T parameter, it was observed that there was a transition to advanced T between the groups. When the N parameter is examined; 63.5% (n=270) N0 cases, 27.5% (n=117) N1 cases, and 8.9% (n=38) N2 cases were detected. When the T parameter remained the same, the cases whose stage increased due to the nodal parameter were 9.4% (n=40), and the cases whose stage increased due to both the increase in the T parameter and the nodal parameter were found to be 6.8% (n=29). The cases whose stage increased because the T parameter had changed were 29.6% (n=126), and the cases whose stage did not change even though the T parameter increased in the 8 th stage were 5.9% (n=25). When the general stage of the patients who underwent surgery is evaluated according to the 8 th TNM, it is seen that a new case distribution emerges in the Stage IIIB group. It was determined that 14 (3.3%) cases passed from Stage IIIA to IIIB with 8 th TNM, with a 5-year survival rate of 28.6%. Stage IIB group is the largest group with 125 (29.4%) cases, and when the subgroup differences between the two stagings are eliminated and the overall survival rates are compared, according to the 8 th TNM, 17.9% (p=0.006) five-year survival increase were observed for Stage IIB cases. Conclusion: The main changes that should be underlined in the 8 th TNM staging, particularly for the patient group undergoing surgery, can be summarized as differentiation of survival expectancy in the early stage by increasing the tumor size subgroups in early-stage lung cancer without lymphatic metastasis, with tumor size becoming important in advancing the T parameter, emphasizing the need for systemic treatment by classifying N1 nodal metastasis as Stage IIB, being included in the T4 group, which is also known as the ‘locally advanced’ disease group, not only by anatomical invasion but also solely for the tumor size. It appears that the 8 th TNM reveals the effects of tumor size on stage in a more effective distribution.